Xilio Therapeutics (NASDAQ:XLO) Shares Down 0.3% – What’s Next?

Xilio Therapeutics, Inc. (NASDAQ:XLO)’s stock price fell 0.3% during trading on Monday . The company traded as low as $7.60 and last traded at $7.68. 22,149 shares changed hands during mid-day trading, a decline of 64% from the average session volume of 61,076 shares. The stock had previously closed at $7.70.

Analysts Set New Price Targets

A number of brokerages recently commented on XLO. Wall Street Zen downgraded shares of Xilio Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings downgraded shares of Xilio Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, May 26th. One research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $28.00.

Xilio Therapeutics Price Performance

The company’s fifty day simple moving average is $8.26 and its 200-day simple moving average is $8.62. The firm has a market capitalization of $50.53 million, a PE ratio of -2.16 and a beta of -0.12.

Xilio Therapeutics (NASDAQ:XLO) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.08. Xilio Therapeutics had a negative net margin of 58.52% and a negative return on equity of 151.42%. The business had revenue of $12.65 million for the quarter, compared to analyst estimates of $8.52 million.

Hedge Funds Weigh In On Xilio Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of XLO. Squarepoint Ops LLC grew its holdings in Xilio Therapeutics by 39.6% in the third quarter. Squarepoint Ops LLC now owns 328,794 shares of the company’s stock worth $277,000 after purchasing an additional 93,338 shares during the last quarter. Empery Asset Management LP purchased a new position in Xilio Therapeutics in the fourth quarter worth $757,000. Renaissance Technologies LLC grew its holdings in Xilio Therapeutics by 68.3% in the fourth quarter. Renaissance Technologies LLC now owns 344,416 shares of the company’s stock worth $220,000 after purchasing an additional 139,716 shares during the last quarter. Jane Street Group LLC purchased a new position in Xilio Therapeutics in the fourth quarter worth $27,000. Finally, State Street Corp grew its holdings in Xilio Therapeutics by 13.7% in the fourth quarter. State Street Corp now owns 186,390 shares of the company’s stock worth $119,000 after purchasing an additional 22,500 shares during the last quarter. 54.29% of the stock is owned by hedge funds and other institutional investors.

About Xilio Therapeutics

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.